{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043582","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.210302+00:00","generated_at":"2026-06-07T18:33:12.674325+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia","bullets":["IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).","Interim CEO Michael Breen says company aims to move GTB-3650 into the clinic expeditiously in 2024.","GTB-3650 is based on the proprietary TriKE NK cell engager platform licensed from University of Minnesota."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043582","json":"https://secwatch.observer/filing/0001493152-23-043582.json","markdown":"https://secwatch.observer/filing/0001493152-23-043582.md","text":"https://secwatch.observer/filing/0001493152-23-043582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315223043582/0001493152-23-043582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315223043582/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:33:12.674325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}